Our press releases

News Our press releases

Forbion invests in Prexton Therapeutics’ EUR 29 million (USD 31 million) Series B financing

in company news

Forbion Capital Partners (“Forbion”), one of the leading Dutch Venture Capital firms investing in world-class healthcare technologies, today announced the closing of a Series B financing round of EUR 29 million (USD 31 million) for Prexton Therapeutics (Prexton). Prexton is a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions.